Authors
Nina Friis-Møller, Rodolphe Thiebaut, Peter Reiss, Rainer Weber, Antonella D'Arminio Monforte, Stephane De Wit, Wafaa El-Sadr, Eric Fontas, Signe Worm, Ole Kirk, Andrew Phillips, Caroline A Sabin, Jens D Lundgren, Matthew G Law, DAD Study Group
Publication date
2010/10/1
Journal
European journal of cardiovascular prevention & rehabilitation
Volume
17
Issue
5
Pages
491-501
Publisher
Oxford University Press
Description
Aims
HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients.
Methods and results
Prospective multinational cohort study. The data set included 22 625 HIV-infected patients from 20 countries in Europe and Australia who were free of CVD at entry into the Data collection on Adverse Effects of Anti-HIV Drugs Study. Using cross-validation methods, separate models were developed to predict the risk of myocardial infarction, coronary heart disease, and a composite CVD endpoint. Model performance was compared with the Framingham score. The models …
Total citations
Scholar articles
N Friis-Møller, R Thiebaut, P Reiss, R Weber… - European journal of cardiovascular prevention & …, 2010